MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 533081 | Name: PKM2 inhibitor 2825-0090

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PKM2 inhibitor 2825-0090 is a Novel pyruvate kinase M2 (PKM2) inhibitor, reducing tumor growth of NSCLC xenografts in vivo.

Chemical Structure

PKM2 inhibitor 2825-0090
PKM2 inhibitor 2825-0090
CAS#313701-92-7

Theoretical Analysis

MedKoo Cat#: 533081

Name: PKM2 inhibitor 2825-0090

CAS#: 313701-92-7

Chemical Formula: C26H26N2O6

Exact Mass: 462.1791

Molecular Weight: 462.50

Elemental Analysis: C, 67.52; H, 5.67; N, 6.06; O, 20.76

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
PKM2 inhibitor 2825-0090
IUPAC/Chemical Name
5-(2,5-Dimethyl-1H-pyrrol-1-yl)-2-hydroxybenzoic acid; 1-(3-Carboxy-4-hydroxy)phenyl-2,5-dimethylpyrrole
InChi Key
RPNDNUTUEQJRBE-UHFFFAOYSA-N
InChi Code
InChI=1S/2C13H13NO3/c2*1-8-3-4-9(2)14(8)10-5-6-12(15)11(7-10)13(16)17/h2*3-7,15H,1-2H3,(H,16,17)
SMILES Code
O=C(O)C1=CC(N2C(C)=CC=C2C)=CC=C1O.CC3=CC=C(C)N3C4=CC=C(O)C(C(O)=O)=C4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 462.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zhou Y, Huang Z, Su J, Li J, Zhao S, Wu L, Zhang J, He Y, Zhang G, Tao J, Zhou J, Chen X, Peng C. Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment. Int J Cancer. 2019 Oct 25. doi: 10.1002/ijc.32756. [Epub ahead of print] PubMed PMID: 31652354. 2: Zhou Q, Sun Y. MLN4924: additional activities beyond neddylation inhibition. Mol Cell Oncol. 2019 May 22;6(5):e1618174. doi: 10.1080/23723556.2019.1618174. eCollection 2019. PubMed PMID: 31528694; PubMed Central PMCID: PMC6736204. 3: Mohammad GH, Vassileva V, Acedo P, Olde Damink SWM, Malago M, Dhar DK, Pereira SP. Targeting Pyruvate Kinase M2 and Lactate Dehydrogenase A Is an Effective Combination Strategy for the Treatment of Pancreatic Cancer. Cancers (Basel). 2019 Sep 16;11(9). pii: E1372. doi: 10.3390/cancers11091372. PubMed PMID: 31527446; PubMed Central PMCID: PMC6770573. 4: Awasthi D, Nagarkoti S, Sadaf S, Chandra T, Kumar S, Dikshit M. Glycolysis dependent lactate formation in neutrophils: A metabolic link between NOX-dependent and independent NETosis. Biochim Biophys Acta Mol Basis Dis. 2019 Dec 1;1865(12):165542. doi: 10.1016/j.bbadis.2019.165542. Epub 2019 Aug 29. PubMed PMID: 31473341. 5: Wong TL, Ng KY, Tan KV, Chan LH, Zhou L, Che N, Hoo RL, Lee TK, Richard S, Lo CM, Man K, Khong PL, Ma S. CRAF methylation by PRMT6 regulates aerobic glycolysis driven hepatocarcinogenesis via ERK-dependent PKM2 nuclear relocalization and activation. Hepatology. 2019 Aug 30. doi: 10.1002/hep.30923. [Epub ahead of print] PubMed PMID: 31469916. 6: Hsieh IS, Gopula B, Chou CC, Wu HY, Chang GD, Wu WJ, Chang CS, Chu PC, Chen CS. Development of Novel Irreversible Pyruvate Kinase M2 Inhibitors. J Med Chem. 2019 Sep 26;62(18):8497-8510. doi: 10.1021/acs.jmedchem.9b00763. Epub 2019 Sep 16. PubMed PMID: 31465224. 7: Shen Y, Chen G, Zhuang L, Xu L, Lin J, Liu L. ARHGAP4 mediates the Warburg effect in pancreatic cancer through the mTOR and HIF-1α signaling pathways. Onco Targets Ther. 2019 Jun 28;12:5003-5012. doi: 10.2147/OTT.S207560. eCollection 2019. PubMed PMID: 31303760; PubMed Central PMCID: PMC6611502. 8: Macpherson JA, Theisen A, Masino L, Fets L, Driscoll PC, Encheva V, Snijders AP, Martin SR, Kleinjung J, Barran PE, Fraternali F, Anastasiou D. Functional cross-talk between allosteric effects of activating and inhibiting ligands underlies PKM2 regulation. Elife. 2019 Jul 2;8. pii: e45068. doi: 10.7554/eLife.45068. PubMed PMID: 31264961; PubMed Central PMCID: PMC6636998. 9: De Rosa V, Monti M, Terlizzi C, Fonti R, Del Vecchio S, Iommelli F. Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells. Int J Mol Sci. 2019 Jun 27;20(13). pii: E3134. doi: 10.3390/ijms20133134. PubMed PMID: 31252559; PubMed Central PMCID: PMC6651622. 10: Liu W, Woolbright BL, Pirani K, Didde R, Abbott E, Kaushik G, Martin P, Hamilton-Reeves J, Taylor JA 3rd, Holzbeierlein JM, Anant S, Lee EK. Tumor M2-PK: A novel urine marker of bladder cancer. PLoS One. 2019 Jun 27;14(6):e0218737. doi: 10.1371/journal.pone.0218737. eCollection 2019. PubMed PMID: 31246990; PubMed Central PMCID: PMC6597081. 11: Kono M, Maeda K, Stocton-Gavanescu I, Pan W, Umeda M, Katsuyama E, Burbano C, Orite SYK, Vukelic M, Tsokos MG, Yoshida N, Tsokos GC. Pyruvate kinase M2 is requisite for Th1 and Th17 differentiation. JCI Insight. 2019 Jun 20;4(12). pii: 127395. doi: 10.1172/jci.insight.127395. eCollection 2019 Jun 20. PubMed PMID: 31217348; PubMed Central PMCID: PMC6629104. 12: Shin S, Kwon YJ, Ye DJ, Baek HS, Kwon TU, Kim D, Chun YJ. Human steroid sulfatase enhances aerobic glycolysis through induction of HIF1α and glycolytic enzymes. Biochim Biophys Acta Mol Basis Dis. 2019 Sep 1;1865(9):2464-2474. doi: 10.1016/j.bbadis.2019.06.005. Epub 2019 Jun 11. PubMed PMID: 31195119. 13: Ge XL, Wang JL, Liu X, Zhang J, Liu C, Guo L. Inhibition of miR-19a protects neurons against ischemic stroke through modulating glucose metabolism and neuronal apoptosis. Cell Mol Biol Lett. 2019 May 31;24:37. doi: 10.1186/s11658-019-0160-2. eCollection 2019. PubMed PMID: 31168302; PubMed Central PMCID: PMC6545018. 14: Suzuki A, Puri S, Leland P, Puri A, Moudgil T, Fox BA, Puri RK, Joshi BH. Subcellular compartmentalization of PKM2 identifies anti-PKM2 therapy response in vitro and in vivo mouse model of human non-small-cell lung cancer. PLoS One. 2019 May 23;14(5):e0217131. doi: 10.1371/journal.pone.0217131. eCollection 2019. PubMed PMID: 31120964; PubMed Central PMCID: PMC6532891. 15: Bi YH, Han WQ, Li RF, Wang YJ, Du ZS, Wang XJ, Jiang Y. Signal transducer and activator of transcription 3 promotes the Warburg effect possibly by inducing pyruvate kinase M2 phosphorylation in liver precancerous lesions. World J Gastroenterol. 2019 Apr 28;25(16):1936-1949. doi: 10.3748/wjg.v25.i16.1936. PubMed PMID: 31086462; PubMed Central PMCID: PMC6487376. 16: Beinat C, Patel CB, Xie Y, Gambhir SS. Evaluation of Glycolytic Response to Multiple Classes of Anti-glioblastoma Drugs by Noninvasive Measurement of Pyruvate Kinase M2 Using [(18)F]DASA-23. Mol Imaging Biol. 2019 Apr 15. doi: 10.1007/s11307-019-01353-2. [Epub ahead of print] PubMed PMID: 30989436. 17: Qi H, Ning X, Yu C, Ji X, Jin Y, McNutt MA, Yin Y. Succinylation-dependent mitochondrial translocation of PKM2 promotes cell survival in response to nutritional stress. Cell Death Dis. 2019 Feb 20;10(3):170. doi: 10.1038/s41419-018-1271-9. PubMed PMID: 30787272; PubMed Central PMCID: PMC6382874. 18: Gao Y, Yang F, Yang XA, Zhang L, Yu H, Cheng X, Xu S, Pan J, Wang K, Li P. Mitochondrial metabolism is inhibited by the HIF1α-MYC-PGC-1β axis in BRAF V600E thyroid cancer. FEBS J. 2019 Apr;286(7):1420-1436. doi: 10.1111/febs.14786. Epub 2019 Mar 5. PubMed PMID: 30768848. 19: Ye G, Qin Y, Wang S, Pan D, Xu S, Wu C, Wang X, Wang J, Ye H, Shen H. Lamc1 promotes the Warburg effect in hepatocellular carcinoma cells by regulating PKM2 expression through AKT pathway. Cancer Biol Ther. 2019;20(5):711-719. doi: 10.1080/15384047.2018.1564558. Epub 2019 Feb 12. PubMed PMID: 30755064; PubMed Central PMCID: PMC6605989. 20: Zhou Q, Li H, Li Y, Tan M, Fan S, Cao C, Meng F, Zhu L, Zhao L, Guan MX, Jin H, Sun Y. Inhibiting neddylation modification alters mitochondrial morphology and reprograms energy metabolism in cancer cells. JCI Insight. 2019 Feb 21;4(4). pii: 121582. doi: 10.1172/jci.insight.121582. eCollection 2019 Feb 21. PubMed PMID: 30668548; PubMed Central PMCID: PMC6478410.